News

Treat HIV-Related Hodgkin's Like Non-HIV Disease


 

FROM THE ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION

Dr. Hentrich had no financial disclosures or conflicts of interest.

Pages

Recommended Reading

FDA Keeping an Eye on New Malignancy Concerns With Lenalidomide
MDedge Hematology and Oncology
Rare Lymphoma Reports Continue in Young Patients on TNF Blockers
MDedge Hematology and Oncology
Low-Dose Irradiation Allays 93% of Gastric MALT Lymphomas at 10 Years
MDedge Hematology and Oncology
Pomalidomide in lenalidomide-refractory multiple myeloma and carfilzomib in refractory and newly diagnosed multiple myeloma
MDedge Hematology and Oncology
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
MDedge Hematology and Oncology
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
MDedge Hematology and Oncology
Chemo Length May Not Affect Survival in Some B-cell Lymphomas
MDedge Hematology and Oncology
Rituximab Maintenance Called "New Standard" for Mantle Cell Lymphoma
MDedge Hematology and Oncology
Rituximab Maintenance Called "New Standard" for Mantle Cell Lymphoma
MDedge Hematology and Oncology
Studies Mixed on Second Cancers After Lenalidomide
MDedge Hematology and Oncology